OncoMatch/Clinical Trials/NCT05723055
Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Is NCT05723055 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Axatilimab and Nivolumab for hodgkin lymphoma.
Treatment: Axatilimab · Nivolumab — The goal of this clinical trial is to study the combination of nivolumab and axatilimab in patients with relapsed/refractory classical Hodgkin Lymphoma. This study will mainly look at if the combination works as expected.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-PD-1 therapy (nivolumab, pembrolizumab, atezolizumab, tislelizumab, durvalumab)
have had prior exposure to anti-PD-1/anti-PDL-1 therapy such as, but not limited to, nivolumab, pembrolizumab, atezolizumab, tislelizumab, and durvalumab
Cannot have received: CSF-1, CSF-1R, and/or IL-34-blocking agents
Previously treated with a CSF-1, CSF-1R, and/or IL-34-blocking agents.
Lab requirements
Blood counts
Platelet count ≥ 50,000/mm3 (unless bone marrow involved); Hemoglobin ≥ 8 g/dL (unless bone marrow involved); ANC ≥.5 × 10^9/L unless bone marrow involvement from classical Hodgkin lymphoma
Kidney function
Estimated creatinine clearance ≥ 50 mL/min by Cockcroft-Gault formula
Liver function
Total Bilirubin ≤ 1.5x institutional ULN (≤ 3x ULN if Gilbert Syndrome); AST(SGOT)/ALT(SGPT) ≤ 3 × Institutional ULN (≤ 5x ULN if liver metastases)
Adequate organ function, without the use of transfusions or growth factors within 7 days, as defined as: Hematologic: Platelet count ≥ 50,000/mm3 (unless bone marrow involved); Hemoglobin ≥ 8 g/dL (unless bone marrow involved); ANC ≥.5 × 10^9/L unless bone marrow involvement from classical Hodgkin lymphoma. Hepatic: Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN). Exceptions include patients with underlying Gilbert Syndrome in whom ≤ 3x institutional upper limit of normal (ULN) of Total Bilirubin will be allowed. AST(SGOT)/ALT(SGPT) ≤ 3 × Institutional ULN. Subjects with liver metastases will be allowed to enroll with AST and ALT levels ≤ 5 x ULN. Renal: Estimated creatinine clearance ≥ 50 mL/min by Cockcroft-Gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Karmanos Cancer Institute · Detroit, Michigan
- Huntsman Cancer Institute at the University of Utah · Salt Lake City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify